

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandra, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/583,076	06/15/2006	Kab-Sig Kim	1728.09	9138
29338 PARK LAW F	7590 12/29/2008 TRM		EXAMINER	
3255 WILSHIRE BLVD			WARE, DEBORAH K	
SUITE 1110 LOS ANGELI	ES. CA 90010		ART UNIT	PAPER NUMBER
	,		1651	
			MAIL DATE	DELIVERY MODE
			12/29/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

# Application No. 10/583 076 KIM ET AL

Applicant(s)

	10/565,076	KIM ET AL.				
Office Action Summary	Examiner	Art Unit	_			
	DEBBIE K. WARE	1651				
The MAILING DATE of this communication app	ears on the cover sheet with the o	orrespondence address	_			
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILUNG D Extension of time may be available under the provisions of 37 CFR 11. and SSN (6) MVR115 from an entity failed or the find morning failed in the failed f	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	J. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
Responsive to communication(s) filed on						
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ This action is non-final.						
3) Since this application is in condition for allowar		secution as to the merits is				
closed in accordance with the practice under E						
Disposition of Claims						
· _						
4)⊠ Claim(s) <u>1-6</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-6</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine	r					
		=vaminer				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☑ objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correct						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	⊢(d) or (f).				
a)⊠ All b)□ Some * c)□ None of:						
<ol> <li>Certified copies of the priority documents</li> </ol>	s have been received.					
<ol><li>Certified copies of the priority documents have been received in Application No</li></ol>						
<ol> <li>Copies of the certified copies of the prior</li> </ol>	rity documents have been receive	ed in this National Stage				
application from the International Bureau	(PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list		d.				
Attachment(a)						
Attachment(s)	4) 🗆 I-t	(DTO 440)				
Notice of References Cited (PTO-892)    Notice of Draftsperson's Patent Drawing Review (PTO-948)	<li>4) Interview Summary Paper No(s)/Mail Day</li>	(F10-413) ate.				
Information Disclosure Statement(s) (PTO/SE/DE)	5) Notice of Informal F					
Paper No(s)/Mail Date	6) Other:					

Art Unit: 1651

#### DETAILED ACTION

Claims 1-6 are presented for examination on the merits.

# Drawings

The drawings are objected to because they are difficult to read because the print is too small and also the photograph copy is not very clear. It is suggested to submit a real photograph and to have the graph drawn larger and to make the print and numbers larger on the graph as well.

### Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-6 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Since the microorganism is recited in the claims, it is essential to the invention recited in those claims. It must therefore be obtainable by a repeatable method set forth in the specification or otherwise be readily available to the public. If the microorganism is not so obtainable or available, the requirements of 35 U.S.C. § 112 may be satisfied

Art Unit: 1651

by a deposit of the microorganism. The specification does not disclose a repeatable process to obtain the microorganism and it is not apparent if the microorganism is readily available to the public.

It is noted that applicants have deposited the organism but there is no indication in the specification as to public availability. If the deposit is made under the terms of the Budapest Treaty, then an affidavit or declaration by applicants, or a statement by an attorney of record over his or her signature and registration number, stating that the specific strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent, would satisfy the deposit requirement made herein.

If the deposit has not been made under the Budapest Treaty, then in order to certify that the deposit meets the criteria set forth in 37 C.F.R. §§ 1.801-1.809, applicants may provide assurance of compliance by an affidavit or declaration, or by a statement by an attorney of record over his or her signature and registration number, showing that:

- (a) during the pendency of this application, access to the invention will be afforded to the Commissioner upon request;
- (b) all restrictions upon availability to the public will be irrevocably removed upon granting of the patent;
- (c) the deposit will be maintained in a public depository for a period of 30 years or 5 years after the last request or for the effective life of the patent, whichever is longer; and

Application/Control Number: 10/583,076 Page 4

Art Unit: 1651

(d) the deposit will be replaced if it should ever become inviable.

Applicant is directed to 37 CFR § 1.807(b) which states:

- (b) A viability statement for each deposit of a biological material defined in paragraph (a) of this section not made under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure must be filed in the application and must contain:
- (1) The name and address of the depository; (2) The name and address of the depositor; (3) The date of deposit;
- (4) The identity of the deposit and the accession number given by the depository;
  (5) The date of the viability test:
  (6) The procedures used to

obtain a sample if the test is not done by the depository; and

(7) A statement that the deposit is capable of reproduction.

Applicant is also directed to 37 CFR § 1.809(d) which states:

- (d) For each deposit made pursuant to these regulations, the specification shall contain:
- (1) The accession number for the deposit:
- (2) The date of the deposit:
- (3) A description of the deposited biological material sufficient to specifically identify it and to permit examination; and
- (4) The name and address of the depository.

## Claim Rejections - 35 USC § 102/103

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that

form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all

obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

Art Unit: 1651

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-6 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Conkling et al (USP 5750386), cited on enclosed PTO-892 Form.

Claims are drawn to a Bacillus amyloliquefaciens having antifungal activity against plant pathogenic fungi and inhibitory effect against plant virus infection.

The reference teach Bacillus amyloliquefaciens (col. 6, lines 29 and 31), which can be utilized an as antifungal agent or substance. The microorganism is effective against powdery mildew such as the one which affects roses, note col. 10, lines 32 and 48-49. Also the reference discloses that the substance and microorganism are effective against tobacco mosaic virus, note col. 10, line 20.

The claims are identical to the teaching of Conkling et al and are therefore, considered to be anticipated by the teachings therein. However, in the alternative that there is some unidentified claim characteristic for which makes for some difference

Art Unit: 1651

between the claims and the reference then the difference is considered to be so slight as to render the claims obvious over the reference. It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to select Bacillus amyloliquefaciens as an antifungal agent because the art clearly recognizes that one of skill used the microorganism to formulate an antifungal agent, etc. Therefore, one of skill would have been motivated to provide for the microorganism because it is well recognized at the time the claimed invention was to possess the same properties as disclosed by Conkling et al. Hence, in the alternative the claims are deemed prima facie obvious over the cited reference

All claims fail to be patentably distinguishable over the state of the art discussed above and cited on the enclosed PTO-892 and/or PTO-1449. Therefore, the claims are properly rejected.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBBIE K. WARE whose telephone number is (571)272-0924. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Deborah K. Ware/ Deborah K. Ware Examiner Art Unit 1651